Prevention of vascular calcification by the endogenous chromogranin A-derived mediator that inhibits osteogenic transdifferentiation
Authors:
Open Access
- 13 October 2021
- journal article
- research article
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 116 (1) , 1-24
Abstract
The adrenal glands participate in cardiovascular (CV) physiology and the pathophysiology of CV diseases through their effects on sodium and water metabolism, vascular tone and cardiac function. In the present study, we identified a new adrenal compound controlling mesenchymal cell differentiation that regulates osteoblastic differentiation in the context of vascular calcification. This peptide was named the “calcification blocking factor” (CBF) due to its protective effect against vascular calcification and is released from chromogranin A via enzymatic cleavage by calpain 1 and kallikrein. CBF reduced the calcium content of cells and thoracic aortic rings under calcifying culture conditions, as well as in aortas from animals treated with vitamin D and nicotine (VDN animals). Furthermore, CBF prevented vascular smooth muscle cell (VSMC) transdifferentiation into osteoblast-like cells within the vascular wall via the sodium-dependent phosphate transporter PIT-1 and by inhibition of NF-κB activation and the subsequent BMP2/p-SMAD pathway. Pulse pressure, a marker of arterial stiffness, was significantly decreased in VDN animals treated with CBF. In line with our preclinical data, CBF concentration is significantly reduced in diseases characterized by increased calcification, as shown in patients with chronic kidney disease. In preparation for clinical translation, the active site of the native 19-AS long native CBF was identified as EGQEEEED. In conclusion, we have identified the new peptide CBF, which is secreted from the adrenal glands and might prevent vascular calcification by inhibition of osteogenic transdifferentiation. The anti-calcific effects of CBF and short active site may therefore promote the development of new tools for the prevention and/or treatment of vascular calcification.Keywords
Funding Information
- Universitätsklinikum RWTH Aachen
This publication has 85 references indexed in Scilit:
- Mice with Hypomorphic Expression of the Sodium-Phosphate Cotransporter PiT1/Slc20a1 Have an Unexpected Normal Bone MineralizationPLOS ONE, 2013
- Bone Morphogenetic Protein‐2 Decreases MicroRNA‐30b and MicroRNA‐30c to Promote Vascular Smooth Muscle Cell CalcificationJournal of the American Heart Association, 2012
- Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expressionKidney International, 2012
- Inhibition of Bone Morphogenetic Protein Signaling Reduces Vascular Calcification and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- A Common Genetic Variant in the 3′-UTR of Vacuolar H + -ATPase ATP6V0A1 Creates a Micro-RNA Motif to Alter Chromogranin A Processing and Hypertension RiskCirculation: Cardiovascular Genetics, 2011
- Mass Spectrometry-Based Neuropeptidomics of Secretory Vesicles from Human Adrenal Medullary Pheochromocytoma Reveals Novel Peptide Products of Prohormone ProcessingJournal of Proteome Research, 2010
- Regulatory mechanisms in vascular calcificationNature Reviews Cardiology, 2010
- Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responsesJournal Of Hypertension, 2010
- Involvement of MAPK signaling molecules and Runx2 in the NELL1‐induced osteoblastic differentiationFEBS Letters, 2007
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003